Jalloul Sarah, Jreij Chris, Karam Karam, Salem Johny, Chaptini Louis
Department of Gastroenterology, Faculty of Medicine, University of Balamand, El Koura, Lebanon.
Department of Internal Medicine, Faculty of Medicine, University of Balamand, El Koura, Lebanon.
Eur J Case Rep Intern Med. 2024 Sep 12;11(10):004832. doi: 10.12890/2024_004832. eCollection 2024.
Dabigatran, a commonly prescribed anticoagulant medication, has been associated with esophagitis, referred to as dabigatran-induced esophagitis (DIE). We report a case of DIE occurring in a patient following left atrial ablation for atrial fibrillation. This case emphasizes the importance of recognizing the possible combined detrimental effects of left atrial ablation and dabigatran on the esophageal mucosa and highlights the clinical and endoscopic characteristics associated with DIE.
Dabigatran-induced esophagitis (DIE) should be considered in patients on dabigatran developing esophageal symptoms after radiofrequency ablation for atrial fibrillation.DIE is a condition characterized clinically by symptoms related to esophageal dysfunction and histologically by significant inflammation of the esophageal mucosa.Physicians should be aware of the signs and symptoms of DIE and must educate patients on proper medication administration to avoid such risks.
达比加群是一种常用的抗凝药物，与食管炎有关，称为达比加群诱导的食管炎（DIE）。我们报告了一例在房颤患者进行左心房消融术后发生DIE的病例。该病例强调了认识左心房消融和达比加群对食管黏膜可能产生的联合有害影响的重要性，并突出了与DIE相关的临床和内镜特征。
对于接受达比加群治疗且在房颤射频消融术后出现食管症状的患者，应考虑达比加群诱导的食管炎（DIE）。DIE在临床上表现为与食管功能障碍相关的症状，组织学上表现为食管黏膜的显著炎症。医生应了解DIE的体征和症状，并必须对患者进行正确用药指导以避免此类风险。
